Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Early Precision Detection Platform for Alzheimer's Disease Based on Multi-Omics Cross-Validation

Early Precision Detection Platform for Alzheimer's Disease Based on Multi-Omics Cross-Validation

Early Precision Detection Platform for Alzheimer's Disease Based on Multi-Omics Cross-Validation

  • The core product of Zhongjia Biotech's AD detection (code AD Plus) is a blood test. Its core task is to accurately determine, through a single routine blood draw, whether amyloid plaque deposition that causes AD exists in the brain when a patient presents with mild cognitive impairment (MCI) or dementia symptoms (early AD).

    Underlying core technology: Instead of conventional enzyme-linked immunoassays, this project adopts spectral analysis. Its advantage is that it can perform absolute quantification of extremely low-abundance pathogenic proteins in blood at the molecular weight level, completely avoiding the cross-reactivity and antibody interference common in conventional antibody-based assays.

    AD biomarker targets: The core indicators measured by the Zhongjia Biotech platform are Aβ42/Aβ40, p-Tau217, p-Tau181, p-Tau231 and T-Tau.

    Exclusive algorithm score: The system inputs the absolute concentration data obtained by spectral analysis into its exclusive statistical algorithm model and outputs a 0-100 Tau Protein Probability Score 2 (Tau2); the higher the score, the greater the probability that AD pathology exists in the patient's brain.


  • Zhongjia Biotech's AD detection project (code AD Plus) is the crystallization of the translation of various interdisciplinary technologies.

    Core founding team (the "iron triangle" structure)

    The founding and development of this project rely heavily on the perfect division of labor among three co-founders: two focused on underlying scientific discoveries and technological breakthroughs, and one focused on clinical translation and commercial breakthrough.

    Qu Shoukang (founder, president and CEO): Mr. Qu Shoukang laid the most fundamental biological target logic for this project; he established which protein fragments, after entering peripheral blood, can still accurately reflect pathological changes in the brain's central nervous system.

    Professor Lian Qizhou (scientific co-founder, founder of the underlying technology): Professor Lian Qizhou innovatively applied spectral analysis-AI to measure the production and clearance rates of extremely trace brain-derived proteins. This underlying spectral analysis technology, which has shone brilliantly in academia, directly became the process cornerstone of this project's precision blood testing platform.

    Professor Xiao Liang (scientific co-founder, core of the Scientific Advisory Board): As the helmsman of this project's clinical trials, Professor Xiao Liang is responsible for crossing the "valley of death" from "laboratory scientific results" to "clinical application." He not only led the long and complex regulatory approval communications (securing medical device recognition for this project) but also extremely successfully carried out hospital implementation, driving this project to market.

    Core R&D and scientific translation executive team

    To upgrade "hand-polished, time-consuming" spectral analysis from university laboratories into a high-throughput, standardized commercial process that can run in certified laboratories, a top-tier industrial-grade scientific team is indispensable.

    Professor Liu Jia (senior R&D director/core scientist): Professor Liu Jia is one of the core PIs (principal investigators) who secured key translational funding for this project in its early stage. She led the internal R&D team to optimize the original experimental protocol into a commercial-grade blood testing kit and algorithm system that meets extremely high quality control standards.

    The team's strategic collaboration model (a closed "industry-academia-research" loop)

    The greatest competitive advantage of this project team is that it still maintains an extremely close "front shop, back factory" binding relationship with Sun Yat-sen University:

    Source of vitality: Sun Yat-sen University's top laboratory (the Alzheimer's Disease Research Center) is responsible for exploring the latest and most cutting-edge pathogenic subtypes and novel phosphorylated Tau protein sites (for example, upgrading from p-Tau181 to the pathologically more sensitive p-Tau217).

    Industrial translation: Once there is a new academic breakthrough, this project's R&D team (led by Professor Liu Jia) will quickly take over, using proprietary reagent formulations, fully automated spectral analyzer optimization, and exclusive statistical algorithms to package it into an in vitro diagnostic (IVD) or LDT service that doctors can order with one click.


  • Zhongjia Biotech is in an absolutely leading position in the commercialization of AD blood testing globally, having moved beyond proof of concept and entered the stage of widespread clinical adoption and global decentralized expansion:

    As early as 2020, Zhongjia Biotech obtained the "Class I Medical Device Filing" and "Class II Medical Device Filing" qualifications. In 2025, the company launched its first-generation AD blood test, becoming the first AD blood testing product in China to enter commercial clinical use. The subsequently iterated AD Plus achieved a qualitative leap in sensitivity and specificity. Currently, through the LDT (clinical laboratory project, carried out at Shenzhen Third People's Hospital) model, the project aims to enable top hospital laboratories in various regions to run AD tests locally, achieving nationwide volume.


  • This project has currently filed 4 invention patents and has 2 papers under review awaiting publication. The intellectual property (IP) moat of this project is extremely deep. Antibody-free biomolecule extraction patent (nanomaterials): Zhongjia Biotech holds an extremely critical underlying preparation process patent that protects the method for directly extracting, isolating, and precisely measuring extremely low-abundance biomarkers (such as Tau) from complex blood matrices without relying on antibody enrichment. This directly builds its "spectral analysis" moat.

    Algorithm and scoring model system: In addition to biochemical-level extraction, this project has rigorous intellectual property protection at the software and data combination level for how to assign different weights to age, ApoE genotype, and multiple protein concentrations to generate an algorithm model with extremely high clinical guiding value.


  • Assessed from both scientific and clinical dimensions, Zhongjia AD Plus is currently one of the AD blood testing products with the highest maturity and strongest clinical trust globally.

    Extremely high diagnostic accuracy (can replace the gold standard): According to top-tier clinical validation data published in authoritative medical journals, the agreement rate between Zhongjia AD Plus test results and expensive "brain amyloid PET scans" or "cerebrospinal fluid (CSF) puncture analysis" is as high as 90% to 99%. In a recent large real-world study (the QUIP II study), it was confirmed that this test can greatly change physicians' clinical decisions, with accuracy far higher than conventional general practitioner diagnosis based on symptoms alone (99% vs 61%).

    The "absolute anti-interference" reliability of the spectral method: Conventional blood tests are prone to "false positives" or "false negatives" if the patient has severe autoimmune disease or other miscellaneous proteins in the blood. Zhongjia's spectral method directly weighs and identifies target proteins of specific molecular weights at the molecular level, greatly reducing biological interference, and its data stability and batch consistency (extremely low CV values) are industry benchmarks.


  • Market demand: the rigid need for "whole-course management" in the era of precision medicine

    Traditional AD diagnosis relies on cerebrospinal fluid (CSF) puncture (invasive, poor patient compliance) or amyloid PET scanning (expensive, scarce equipment, difficult to popularize). A peripheral blood precision detection platform based on multi-omics (genomics, transcriptomics, proteomics, metabolomics) precisely addresses the following three major rigid demand scenarios:

    "Early warning and triage" in the preclinical stage: Molecular pathological changes of neurodegenerative lesions (such as peripheral inflammatory markers GFAP, NfL, p-Tau217, etc.) usually appear 15-20 years earlier than clinical symptoms. A multi-omics platform can integrate genetic susceptibility and real-time functional metabolism to achieve precise screening when patients are in the subjective cognitive decline (SCD) or mild cognitive impairment (MCI) stage, winning a golden window for early intervention.

    "Companion diagnostics and companion stratification" for targeted drugs: The new generation of AD drugs (whether monoclonal antibodies or cell innovative drugs) impose strict requirements on patients' pathological classification. Multi-omics cross-validation can not only detect Aβ or Tau but also assess microenvironment indicators such as microglial activation status, chronic neuroinflammation, and mitochondrial dysfunction, helping clinicians precisely screen patient subtypes suitable for specific targeted therapies (such as neural microenvironment remodeling therapy).

    Longitudinal efficacy monitoring and dynamic follow-up: After cell therapy or immune-modifying treatment, the clearance of pathological proteins and the repair of the neural microenvironment require dynamic assessment. Multi-omics detection guided by mass spectrometry (MS) or ultrasensitive single-molecule array (Simoa) can dynamically track changes in peripheral blood indicators with an extremely low coefficient of variation (RSD), serving as a surrogate endpoint to evaluate drug efficacy.

    Prospects and core moat: from "one-dimensional signals" to "multi-dimensional mutual verification"

    The biggest pain point of traditional AD detection (such as simply measuring plasma Aβ42/Aβ40) is strong peripheral blood matrix interference and small magnitude of change (only about 10-15% reduction in AD patients), which easily leads to false negatives. The future prospects of this platform are based on the deep technical barriers it has established:

    Ultra-high precision brought by cross-validation: Horizontal mutual verification is achieved through transcriptomic RNA expression programs, proteomic damage markers, and metabolomic lipid stress. Abnormalities in a single omics may be caused by peripheral solid tumors or nonspecific inflammation, but combined multi-omics analysis can eliminate peripheral noise through machine learning (ML) algorithms, pushing both diagnostic sensitivity and specificity above 90%, reaching a diagnostic-grade standard that can replace PET scanning.

    Achieving true precision stratification: AD is highly heterogeneous. A multi-omics platform can classify AD into subtypes such as "immune-inflammatory type," "mitochondrial metabolic disorder type," and "synaptic function impairment type" according to molecular characteristics, thereby truly guiding personalized precision medication and securing the source of the next generation of clinical diagnosis and treatment standards.

    Commercialization pain points and breakthrough paths

    To successfully bring a cutting-edge multi-omics platform to large-scale clinical application and the in vitro diagnostics market, the following industrialization barriers must be overcome:

    Standardization of complex data flows and solidification of algorithms. Pain point: Cross-omics data (large-scale sequencing, high-throughput mass spectrometry, multi-target immunoassays) have extremely high data dimensions, and instrument drift and systematic errors between different batches and different laboratories can easily cause algorithm failure. Breakthrough path: It is necessary to develop standardized pre-processing processes (CMC-grade sample specifications) and solidified embedded AI analysis software (for example, developing standalone automated pipeline software similar to "SERS-MLPro"). Raw spectral, mass spectrometry, or sequencing data are automatically baseline-corrected and data-augmented to ensure the robustness of prediction results.

    "Democratization" of clinical accessibility and testing costs. Pain point: Full-omics testing (such as whole-exome sequencing + deep mass spectrometry screening) is costly and time-consuming, making it difficult to use as large-scale physical examination or screening programs. Breakthrough path: Adopt the translation path of "discovery omics-targeted combination." In the R&D stage, use full-omics to discover Convergent Biology features of key pathways, and at commercialization streamline them into a "specific core multi-omics Panel" (for example, several specific high-value protein biomarkers + core metabolite mass spectrometry quantification + susceptibility gene locus chips). This greatly reduces preparation and kit costs to adapt to the turnaround rates of clinical laboratories and third-party independent medical laboratories (ICL).

    Refined positioning of commercial implementation scenarios. Pain point: Traditional tertiary hospitals have strict review of billing items and medical insurance access for emerging multi-omics combined diagnostics. Breakthrough path: Adopt a dual-track commercialization strategy. B-end (pharmaceutical companies): Prioritize entry into the clinical trials of multinational pharmaceutical companies and top domestic CGT (cell and gene therapy) companies as key companion diagnostic tools (CDx) for Phase III clinical trials or breakthrough therapy pipelines, paid for by pharmaceutical R&D budgets. C-end (clinical/physical examination): Bundle with urban inclusive insurance or precision physical examination packages for high-risk elderly populations, leveraging the health economics advantage of "early screening, early blocking, and reducing late-stage care costs of hundreds of thousands" to drive the self-pay and commercial insurance markets.

    Comprehensive strategic prospect summary

    Strategic judgment: The AD peripheral blood precision detection platform based on multi-omics cross-validation is not a minor adjustment of traditional testing technology but the infrastructure of the era of AD regenerative medicine and precision pharmacy. A tens-of-billions rigid blue ocean: With global aging and the evolution of ultrasensitive biomarker detection technology, the AD early screening and efficacy monitoring market is recognized in the next decade as one of the most explosive hundred-billion-level super tracks in the IVD field. An industry moat that is difficult to replicate: Taking the lead in establishing a multi-omics database based on large-scale, full-time real-world clinical cohorts, and completing algorithm solidification and kit translation, will enable it to hold the absolute right to define early AD diagnosis and pricing power in the health and precision medicine industries.


Related Qualifications